Skip to content

December 13, 2024
2024 Report on TB Research Funding Trends
A new report released today by Treatment Action Group (TAG) and Stop TB Partnership found that cumulative funding for tuberculosis (TB) research and development (R&D) in 2023 reached only 24% of the annual $5 billion funding target agreed by countries at the United Nations High-Level Meeting (HLM) on TB in…

December 9, 2024
Cheat Sheets for Tuberculosis Activists
TAG’s Cheat Sheets for Tuberculosis Activists are designed to help advocates navigate the range of tools in use and in the research pipeline.

November 26, 2024
TAGline November 2024
This year’s edition of TAGline takes stock of the state of the HIV, TB, and HCV pandemics worldwide, and advances bold visions for what a future without them must look like.

November 20, 2024
2024 TAG Update
As we approach the end of 2024, we want to share with you some of the remarkable progress we’ve made together, and you’ll see some of our work in the 2024 TAG Update.

July 18, 2024
2024 Pipeline Report
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).

July 17, 2024
2023 Annual Report
We’re pleased to share with you our latest Annual Report, which highlights everything we accomplished in 2023.

June 26, 2024
Call For New Global TB CAB Members
On behalf of the Global Tuberculosis Community Advisory Board (TB CAB), we’re excited to announce a call for new member applications.

June 11, 2024
Frequently Asked Questions on Microarray Patches (MAPs)
Microarray patches (MAPs) are arrays of microneedles that stick to your skin like a bandage, offering a noninvasive mechanism for drug administration.

May 10, 2024
An Activist’s Guide to Rifapentine – TB Preventive Treatment: 3HP and 1 HP
Rifapentine, an off-patent drug that’s been around since the 1960s, is the cornerstone of the two most effective regimens to prevent tuberculosis (TB) in people at risk of the disease.

Back To Top